Update on the management of unusual neuroendocrine tumors: Pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 120-133

  Strosberg, Jonathan R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINE; CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HYDROCORTISONE; MITOTANE; MOTESANIB; NORADRENALIN; PLACEBO; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STEROID HORMONE; STREPTOZOCIN; SUNITINIB; UNINDEXED DRUG; VANDETANIB; VANILMANDELIC ACID; VASCULOTROPIN RECEPTOR; VINCRISTINE; VON HIPPEL LINDAU PROTEIN;

ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL INSUFFICIENCY; ADRENALECTOMY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIAPHORESIS; DIARRHEA; DIGITAL SUBTRACTION ANGIOGRAPHY; DISEASE DURATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HEADACHE; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LAPAROSCOPIC ADRENALECTOMY; LAPAROSCOPIC SURGERY; MAGNETIC RESONANCE ANGIOGRAPHY; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; NEUROENDOCRINE SYSTEM; NEUROENDOCRINE TUMOR; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; SOMNOLENCE; THYROID MEDULLARY CARCINOMA; THYROID SURGERY; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR LOCALIZATION; WORLD HEALTH ORGANIZATION;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84873388416     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.009     Document Type: Article

References (133)

1. D. Erickson, Y.C. Kudva, M.J. Ebersold Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients J Clin Endocrinol Metab 86 2001 5210 5216
2. G. Stenstrom, K. Svardsudd Pheochromocytoma in Sweden 1958-1981 An analysis of the National Cancer Registry Data Acta Med Scand 220 1986 225 232
3. S.H. Golden, K.A. Robinson, I. Saldanha, B. Anton, P.W. Ladenson Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review J Clin Endocrinol Metab 94 2009 1853 1878
4. E.L. Bravo, R.W. Gifford Jr Current concepts Pheochromocytoma: diagnosis, localization and management N Engl J Med 311 1984 1298 1303
5. E.E. Elder, G. Elder, C. Larsson Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor J Surg Oncol 89 2005 193 201
6. J.H. Lee, F. Barich, L.H. Karnell National Cancer Data Base report on malignant paragangliomas of the head and neck Cancer 94 2002 730 737
7. C.C. Boedeker, G.J. Ridder, J. Schipper Paragangliomas of the head and neck: diagnosis and treatment Fam Cancer 4 2005 55 59
8. M.A. Kinney, B.J. Narr, M.A. Warner Perioperative management of pheochromocytoma J Cardiothorac Vasc Anesth 16 2002 359 369
9. W.T. Shen, R. Grogan, M. Vriens, O.H. Clark, Q.Y. Duh One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy Arch Surg 145 2010 893 897
10. D. Karasek, Z. Frysak, K. Pacak Genetic testing for pheochromocytoma Curr Hypertens Rep 12 2010 456 464
11. B. Wangberg, A. Muth, A. Khorram-Manesh Malignant pheochromocytoma in a population-based study: survival and clinical results Ann N Y Acad Sci 1073 2006 512 516
12. G. Eisenhofer, M.M. Walther, T.T. Huynh Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes J Clin Endocrinol Metab 86 2001 1999 2008
13. M.H. Shen, P.S. Harper, M. Upadhyaya Molecular genetics of neurofibromatosis type 1 (NF1) J Med Genet 33 1996 2 17
14. M.M. Walther, J. Herring, E. Enquist, H.R. Keiser, W.M. Linehan von Recklinghausen's disease and pheochromocytomas J Urol 162 1999 1582 1586
15. B.E. Baysal, R.E. Ferrell, J.E. Willett-Brozick Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma Science 287 2000 848 851
16. S. Niemann, U. Muller Mutations in SDHC cause autosomal dominant paraganglioma, type 3 Nat Genet 26 2000 268 270
17. D. Astuti, F. Latif, A. Dallol Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma Am J Hum Genet 69 2001 49 54
18. J.P. Bayley, H.P. Kunst, A. Cascon SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma Lancet Oncol 11 2010 366 372
19. M. Jafri, E.R. Maher The genetics of phaeochromocytoma: using clinical features to guide genetic testing Eur J Endocrinol 166 2012 151 158
20. G. Eisenhofer, D.S. Goldstein, I.J. Kopin, J.R. Crout Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor Endocr Pathol 14 2003 193 212
21. A.M. Sawka, R. Jaeschke, R.J. Singh, W.F. Young Jr A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines J Clin Endocrinol Metab 88 2003 553 558
22. J.W. Lenders, K. Pacak, M.M. Walther Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287 2002 1427 1434
23. T.J. Welch, P.F. Sheedy 2nd, J.A. van Heerden, S.G. Sheps, R.R. Hattery, D.H. Stephens Pheochromocytoma: value of computed tomography Radiology 148 1983 501 503
24. J.W. Reinig, J.L. Doppman, A.J. Dwyer, A.R. Johnson, R.H. Knop Adrenal masses differentiated by MR Radiology 158 1986 81 84
25. J.C. Sisson, M.S. Frager, T.W. Valk Scintigraphic localization of pheochromocytoma N Engl J Med 305 1981 12 17
26. K. Pacak, G. Eisenhofer, H. Ahlman Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005 Nat Clin Pract Endocrinol Metab 3 2007 92 102
27. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-Analysis J Clin Endocrinol Metab 95 2010 2596 2606
28. 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma Nucl Med Commun 32 2011 575 582
29. C. Trampal, H. Engler, C. Juhlin, M. Bergstrom, B. Langstrom Pheochromocytomas: detection with 11C hydroxyephedrine PET Radiology 230 2004 423 428
30. S.J. Stoeckli, B. Schuknecht, H. Alkadhi, U. Fisch Evaluation of paragangliomas presenting as a cervical mass on color-coded Doppler sonography Laryngoscope 112 2002 143 146
31. M.S. Sajid, G. Hamilton, D.M. Baker A multicenter review of carotid body tumour management Eur J Vasc Endovasc Surg 34 Aug 2007 127 130
32. K.A. Vanderveen, S.M. Thompson, M.R. Callstrom Biopsy of pheochromocytomas and paragangliomas: potential for disaster Surgery 146 2009 1158 1166
33. K. Hu, M.S. Persky Multidisciplinary management of paragangliomas of the head and neck, Part 1 Oncology (Williston Park) 17 2003 983 993
34. R.I. Linnoila, H.R. Keiser, S.M. Steinberg, E.E. Lack Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features Hum Pathol 21 1990 1168 1180
35. M.R. Clarke, R.J. Weyant, C.G. Watson, S.E. Carty Prognostic markers in pheochromocytoma Hum Pathol 29 1998 522 526
36. E.E. Elder, D. Xu, A. Hoog KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma Mod Pathol 16 2003 246 255
37. K. Pacak Preoperative management of the pheochromocytoma patient J Clin Endocrinol Metab 92 2007 4069 4079
38. S. Kocak, S. Aydintug, N. Canakci Alpha blockade in preoperative preparation of patients with pheochromocytomas Int Surg 87 2002 191 194
39. T.N. Weingarten, J.P. Cata, J.F. O'Hara Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma Urology 76 2010 508
40. L. Sibal, A. Jovanovic, S.C. Agarwal Phaeochromocytomas presenting as acute crises after beta blockade therapy Clin Endocrinol (Oxf) 65 2006 186 190
41. J. Steinsapir, A.A. Carr, L.M. Prisant, E.D. Bransome Jr Metyrosine and pheochromocytoma Arch Intern Med 157 1997 901 906
42. M.K. Walz, R. Gwosdz, S.L. Levin Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia World J Surg 32 2008 847 853
43. S.J. Wang, M.B. Wang, T.M. Barauskas, T.C. Calcaterra Surgical management of carotid body tumors Otolaryngol Head Neck Surg 123 2000 202 206
44. R.W. Hinerman, R.J. Amdur, C.G. Morris, J. Kirwan, W.M. Mendenhall Definitive radiotherapy in the management of paragangliomas arising in the head and neck: a 35-year experience Head Neck 30 2008 1431 1438
45. L. Amar, A. Servais, A.P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, P.F. Plouin Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma J Clin Endocrinol Metab 90 2005 2110 2116
46. O.H. Clark, A.B. Benson 3rd, J.D. Berlin NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors J Natl Compr Canc Netw 7 2009 712 747
47. N.A. Samaan, R.C. Hickey, P.E. Shutts Diagnosis, localization, and management of pheochromocytoma Pitfalls and follow-up in 41 patients Cancer 62 1988 2451 2460
48. G. Eisenhofer, S.R. Bornstein, F.M. Brouwers Malignant pheochromocytoma: current status and initiatives for future progress Endocr Relat Cancer 11 2004 423 436
49. H. Huang, J. Abraham, E. Hung Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients Cancer 113 2008 2020 2028
50. A.M. Joshua, S. Ezzat, S.L. Asa Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma J Clin Endocrinol Metab 94 2009 5 9
51. C. Jimenez, M.E. Cabanillas, L. Santarpia Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors J Clin Endocrinol Metab 94 2009 386 391
52. S.D. Safford, R.E. Coleman, J.P. Gockerman Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma Surgery 134 2003 956 962
53. K.C. Loh, P.A. Fitzgerald, K.K. Matthay, P.P. Yeo, D.C. Price The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients J Endocrinol Invest 20 1997 648 658
54. S. Gonias, R. Goldsby, K.K. Matthay Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma J Clin Oncol 27 2009 4162 4168
55. S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S, 1985-1995 Cancer 83 1998 2638 2648
56. S. Leboulleux, E. Baudin, J.P. Travagli, M. Schlumberger Medullary thyroid carcinoma Clin Endocrinol (Oxf) 61 2004 299 310
57. M.F. Saad, N.G. Ordonez, R.K. Rashid Medullary carcinoma of the thyroid A study of the clinical features and prognostic factors in 161 patients Medicine (Baltimore) 63 1984 319 342
58. G.W. Randolph, D. Maniar Medullary carcinoma of the thyroid Cancer Control 7 2000 253 261
59. C.G. Mathew, K.S. Chin, D.F. Easton A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10 Nature 328 1987 527 528
60. H. Donis-Keller, S. Dou, D. Chi Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC Hum Mol Genet 2 1993 851 856
61. R.M. Hofstra, R.M. Landsvater, I. Ceccherini A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma Nature 367 1994 375 376
62. R. Elisei, C. Romei, B. Cosci RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center J Clin Endocrinol Metab 92 2007 4725 4729
63. C. Eng, L.M. Mulligan, D.P. Smith Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma Clin Endocrinol (Oxf) 43 1995 123 127
64. R.T. Kloos, C. Eng, D.B. Evans Medullary thyroid cancer: management guidelines of the American Thyroid Association Thyroid 19 2009 565 612
65. D.J. Marsh, D.L. Learoyd, S.D. Andrew Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma Clin Endocrinol (Oxf) 44 1996 249 257
66. R. Elisei, B. Cosci, C. Romei Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study J Clin Endocrinol Metab 93 2008 682 687
67. S. Roman, R. Lin, J.A. Sosa Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases Cancer 107 2006 2134 2142
68. H.J. Wolfe, R.A. DeLellis, E.F. Voelkel, A.H. Tashjian Jr Distribution of calcitonin-containing cells in the normal neonatal human thyroid gland: a correlation of morphology with peptide content J Clin Endocrinol Metab 41 1975 1076 1081
69. J.F. Moley, M.K. DeBenedetti Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection Ann Surg 229 1999 880 887
70. A. Machens, S. Hauptmann, H. Dralle Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer World J Surg 31 2007 1960 1965
71. M.A. Kouvaraki, S.E. Shapiro, B.D. Fornage Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer Surgery 134 2003 946 954
72. R.M. Tuttle, D.W. Ball, D. Byrd Medullary carcinoma J Natl Compr Canc Netw 8 2010 512 530
73. S.B. Edge, D.R. Byrd, C.C. Compton AJCC cancer staging manual 7th ed. 2010 Springer Chicago
74. G. Mendelsohn, S.B. Baylin, S.H. Bigner, S.A. Wells Jr, J.C. Eggleston Anaplastic variants of medullary thyroid carcinoma: a light-microscopic and immunohistochemical study Am J Surg Pathol 4 1980 333 341
75. K.Y. Lam, M.C. Lui, C.Y. Lo Cytokeratin expression profiles in thyroid carcinomas Eur J Surg Oncol 27 2001 631 635
76. R.A. DeLellis, A.H. Rule, I. Spiler, L. Nathanson, A.H. Tashjian Jr, H.J. Wolfe Calcitonin and carcinoembryonic antigen as tumor markers in medullary thyroid carcinoma Am J Clin Pathol 70 1978 587 594
77. L.E. Tisell, A. Oden, A. Muth The Ki67 index a prognostic marker in medullary thyroid carcinoma Br J Cancer 89 2003 2093 2097
78. J.A. van Heerden, C.S. Grant, H. Gharib, I.D. Hay, D.M. Ilstrup Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma Ann Surg 212 1990 395 400
79. C. Scollo, E. Baudin, J.P. Travagli Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer J Clin Endocrinol Metab 88 2003 2070 2075
80. H. Dralle, I. Damm, G.F. Scheumann Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma Surg Today 24 1994 112 121
81. J.F. Moley Medullary thyroid carcinoma: management of lymph node metastases J Natl Compr Canc Netw 8 2010 549 556
82. L. Fugazzola, A. Pinchera, F. Luchetti Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma Int J Biol Markers 9 1994 21 24
83. A. Miyauchi, T. Onishi, S. Morimoto Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma Ann Surg 199 1984 461 466
84. A. Laure Giraudet, A. Al Ghulzan, A. Auperin Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times Eur J Endocrinol 158 2008 239 246
85. G. Mendelsohn, S.A. Wells Jr, S.B. Baylin Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma An immunohistochemical study in early, localized, and virulent disseminated stages of disease Cancer 54 1984 657 662
86. L.M. Brunt, S.A. Wells Jr Advances in the diagnosis and treatment of medullary thyroid carcinoma Surg Clin North Am 67 1987 263 279
87. N.A. Samaan, P.N. Schultz, R.C. Hickey Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy J Clin Endocrinol Metab 67 1988 801 805
88. J. Brierley, R. Tsang, W.J. Simpson, M. Gospodarowicz, S. Sutcliffe, T. Panzarella Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control Thyroid 6 1996 305 310
89. S.R. Martinez, S.H. Beal, A. Chen, S.L. Chen, P.D. Schneider Adjuvant external beam radiation for medullary thyroid carcinoma J Surg Oncol 102 2010 175 178
90. C. Rodriguez-Antona, J. Pallares, C. Montero-Conde Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 17 2010 7 16
91. S.A. Wells Jr, B.G. Robinson, R.F. Gagel Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
92. R. Kurzrock, S.I. Sherman, D.W. Ball Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J Clin Oncol 29 2011 2660 2666
93. M.J. Schlumberger, R. Elisei, L. Bastholt Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer J Clin Oncol 27 2009 3794 3801
94. E.T. Lam, M.D. Ringel, R.T. Kloos Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 28 2010 2323 2330
95. L.L. Carr, D.A. Mankoff, B.H. Goulart Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation Clin Cancer Res 16 2010 5260 5268
96. L.T. Wu, S.D. Averbuch, D.W. Ball, A. de Bustros, S.B. Baylin, W.P. McGuire III Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine Cancer 73 1994 432 436
97. M. Nocera, E. Baudin, G. Pellegriti, A.F. Cailleux, C. Mechelany-Corone, M. Schlumberger Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine Groupe d'Etude des Tumeurs a Calcitonine (GETC) Br J Cancer 83 2000 715 718
98. A.P. Dackiw, J.E. Lee, R.F. Gagel, D.B. Evans Adrenal cortical carcinoma World J Surg 25 2001 914 926
99. F. Crucitti, R. Bellantone, A. Ferrante, M. Boscherini, P. Crucitti The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients The ACC Italian Registry Study Group Surgery 119 1996 161 170
100. C.A. Koch, K. Pacak, G.P. Chrousos The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors J Clin Endocrinol Metab 87 2002 5367 5384
101. H.T. Lynch, B. Radford, J.F. Lynch SBLA syndrome revisited Oncology 47 1990 75 79
102. M.L. Brandi, R.F. Gagel, A. Angeli Guidelines for diagnosis and therapy of MEN type 1 and type 2 J Clin Endocrinol Metab 86 2001 5658 5671
103. S. Marx, A.M. Spiegel, M.C. Skarulis, J.L. Doppman, F.S. Collins, L.A. Liotta Multiple endocrine neoplasia type 1: clinical and genetic topics Ann Intern Med 129 1998 484 494
104. P.S. Soon, K.L. McDonald, B.G. Robinson, S.B. Sidhu Molecular markers and the pathogenesis of adrenocortical cancer Oncologist 13 2008 548 561
105. M. Reincke, M. Karl, W.H. Travis p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies J Clin Endocrinol Metab 78 1994 790 794
106. H. Ohgaki, P. Kleihues, P.U. Heitz p53 mutations in sporadic adrenocortical tumors Int J Cancer 54 1993 408 410
107. C. Gicquel, X. Bertagna, H. Schneid Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors J Clin Endocrinol Metab 78 1994 1444 1453
108. C. Gicquel, M.L. Raffin-Sanson, V. Gaston Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors J Clin Endocrinol Metab 82 1997 2559 2565
109. L. Ng, J.M. Libertino Adrenocortical carcinoma: diagnosis, evaluation and treatment J Urol 169 2003 5 11
110. B. Allolio, M. Fassnacht Clinical review: adrenocortical carcinoma: clinical update J Clin Endocrinol Metab 91 2006 2027 2037
111. J.P. Luton, S. Cerdas, L. Billaud Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy N Engl J Med 322 1990 1195 1201
112. C. Bertagna, D.N. Orth Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978) Am J Med 71 1981 855 875
113. A.A. Kasperlik-Zaluska, B.M. Migdalska, S. Zgliczynski, A.M. Makowska Adrenocortical carcinoma A clinical study and treatment results of 52 patients Cancer 75 1995 2587 2591
114. G.W. Boland, M.J. Lee, G.S. Gazelle, E.F. Halpern, M.M. McNicholas, P.R. Mueller Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature AJR Am J Roentgenol 171 1998 201 204
115. C.L. Schultz, J.R. Haaga, B.D. Fletcher, R.J. Alfidi, M.A. Schultz Magnetic resonance imaging of the adrenal glands: a comparison with computed tomography AJR Am J Roentgenol 143 1984 1235 1240
116. A. Chang, H.S. Glazer, J.K. Lee, D. Ling, J.P. Heiken Adrenal gland: MR imaging Radiology 163 1987 123 128
117. A. Becherer, H. Vierhapper, C. Potzi FDG-PET in adrenocortical carcinoma Cancer Biother Radiopharm 16 2001 289 295
118. S. Leboulleux, C. Dromain, G. Bonniaud Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography J Clin Endocrinol Metab 91 2006 920 925
119. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng World Health Organization classification of tumours, pathology, and genentics of tumours of endocrine organs 2004 IARC Press Lyon
120. P. Komminoth, J. Roth, S. Schroder, P. Saremaslani, P.U. Heitz Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas Implications for the differential diagnosis of adrenal gland tumors Lab Invest 72 1995 424 431
121. M.L. Enriquez, P. Lal, A. Ziober, L. Wang, J.E. Tomaszewski, Z. Bing The use of immunohistochemical expression of SF-1 and EMA in distinguishing adrenocortical tumors from renal neoplasms Appl Immunohistochem Mol Morphol 20 2012 141 145
122. L.M. Weiss, L.J. Medeiros, A.L. Vickery Jr Pathologic features of prognostic significance in adrenocortical carcinoma Am J Surg Pathol 13 1989 202 206
123. S. Aubert, A. Wacrenier, X. Leroy Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors Am J Surg Pathol 26 2002 1612 1619
124. S.P. Hedican, F.F. Marshall Adrenocortical carcinoma with intracaval extension J Urol 158 1997 2056 2061
125. B.D. Saunders, G.M. Doherty Laparoscopic adrenalectomy for malignant disease Lancet Oncol 5 2004 718 726
126. G. Dickstein, C. Shechner, E. Arad, L.A. Best, O. Nativ Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 83 1998 3100 3103
127. M. Terzolo, A. Angeli, M. Fassnacht Adjuvant mitotane treatment for adrenocortical carcinoma N Engl J Med 356 2007 2372 2380
128. S. Hahner, M. Fassnacht Mitotane for adrenocortical carcinoma treatment Curr Opin Investig Drugs 6 2005 386 394
129. H.R. Haak, J. Hermans, C.J. van de Velde Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients Br J Cancer 69 1994 947 951
130. A.M. Hutter Jr, D.E. Kayhoe Adrenal cortical carcinoma Results of treatment with o,p'DDD in 138 patients Am J Med 41 1966 581 592
131. A. Berruti, M. Terzolo, P. Sperone Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr Relat Cancer 12 2005 657 666
132. T.S. Khan, H. Imam, C. Juhlin Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use Ann Oncol 11 2000 1281 1287
133. M. Fassnacht, M. Terzolo, B. Allolio Combination chemotherapy in advanced adrenocortical carcinoma N Engl J Med 366 2012 2189 2197